Corrigendum to "Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur Urol 84(5) (2023) 449-454].Elizabeth R Plimack,Thomas Powles,Viktor Stus,Rustem Gafanov,Dmitry Nosov,Tom Waddell,Boris Alekseev,Frédéric Pouliot,Bohuslav Melichar,Denis Soulières,Delphine Borchiellini,Raymond S McDermott,Ihor Vynnychenko,Yen-Hwa Chang,Satoshi Tamada,Michael B Atkins,Chenxiang Li,Rodolfo Perini, L Rhoda Molife,Jens Bedke, Brian I RiniEuropean urology（2023）引用 0|浏览11暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
